| 2027-04-01in 219 d | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | ALNYAlnylam Pharmaceuticals | — | Acute Hepatic Porphyria | Recruiting |
| 2027-04-01in 219 d | Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom | AZNAstraZeneca | — | Chronic Lymphocytic Leukemia, CLL | Recruiting |
| 2027-04-01in 219 d | CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction | BCDABioCardia, Inc. | Not applicable | Ischemic Heart Failure | Recruiting |
| 2027-04-01in 219 d | A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation | BSXBoston Scientific Corporation | — | Atrial Fibrillation | Active, not recruiting |
| 2027-04-01in 219 d | Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares | CSTLCastle Biosciences Incorporated | — | Atopic Dermatitis | Recruiting |
| 2027-04-01in 219 d | Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage . | OR.PAL'Oreal | Not applicable | Photodamage of the Face, Anti Aging | Not yet recruiting |
| 2027-04-02in 220 d | A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) | AZNAstraZeneca | Phase 1/2 | Staphylococcus Aureus | Recruiting |
| 2027-04-04in 222 d | Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | SNYSanofi | Phase 1 | Respiratory Syncytial Virus | Recruiting |
| 2027-04-05in 223 d | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | SNYSanofi | Phase 3 | Plasma Cell Myeloma | Active, not recruiting |
| 2027-04-06in 224 d | A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy | 4523.TEisai Inc. | Phase 2 | Epilepsy and Seizure Disorders | Active, not recruiting |
| 2027-04-06in 224 d | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | AZNAstraZeneca | Phase 3 | Ovarian Cancer | Active, not recruiting |
| 2027-04-06in 224 d | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Cystic Fibrosis | Active, not recruiting |
| 2027-04-06in 224 d | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Diabetic Peripheral Neuropathic Pain | Recruiting |
| 2027-04-07in 225 d | A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight | NVONovo Nordisk A/S | Phase 1 | Obesity | Recruiting |
| 2027-04-08in 226 d | A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight | NVONovo Nordisk A/S | Phase 1 | Overweight | Recruiting |
| 2027-04-08in 226 d | A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission | SNYSanofi | Phase 2 | Microscopic Colitis | Recruiting |
| 2027-04-09in 227 d | An Ophthalmic Safety Study in Patients With Breast Cancer | AZNAstraZeneca | — | Ophthalmic Safety in Patients With Breast Cancer | Active, not recruiting |
| 2027-04-09in 227 d | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia | AZNAstraZeneca | Phase 1 | Healthy Participants, Dyslipidemia | Recruiting |
| 2027-04-09in 227 d | A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. | AZNAstraZeneca | Phase 1 | Obesity | Recruiting |
| 2027-04-10in 228 d | A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | AMGNAmgen | Phase 1 | Asthma | Active, not recruiting |
| 2027-04-10in 228 d | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | PFEPfizer | Phase 1 | Multiple Myeloma | Recruiting |
| 2027-04-13in 231 d | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | AMGNAmgen | Phase 2 | Neuromyelitis Optica Spectrum Disorder | Recruiting |
| 2027-04-13in 231 d | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment | INCYIncyte Corporation | Phase 1 | Hepatic Insufficiency, Liver Diseases | Recruiting |
| 2027-04-13in 231 d | A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | NVONovo Nordisk A/S | Phase 1 | Overweight | Recruiting |
| 2027-04-14in 232 d | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | BMRNBioMarin Pharmaceutical | Phase 1/2 | Duchenne Muscular Dystrophy | Active, not recruiting |
| 2027-04-19in 237 d | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | AMGNAmgen | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| 2027-04-20in 238 d | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | AZNAstraZeneca | Phase 3 | Breast Cancer | Recruiting |
| 2027-04-20in 238 d | Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | AZNAstraZeneca | Phase 2 | Clostridioides Difficile Infection | Recruiting |
| 2027-04-21in 239 d | A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity | PFEPfizer | Phase 1 | Obesity | Not yet recruiting |
| 2027-04-24in 242 d | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) | AMGNAmgen | Phase 1 | Lung Cancer | Recruiting |
| 2027-04-24in 242 d | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | REGNRegeneron Pharmaceuticals | Phase 4 | Asthma | Active, not recruiting |
| 2027-04-25in 243 d | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | ALM.MCAlmirall, S.A. | Phase 3 | Atopic Dermatitis | Active, not recruiting |
| 2027-04-25in 243 d | A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) | PFEPfizer | Phase 2 | Gram-negative Bacterial Infection | Recruiting |
| 2027-04-25in 243 d | A Study of PYX-201 in Advanced Solid Tumors | PYXSPyxis Oncology, Inc | Phase 1 | Solid Tumors | Recruiting |
| 2027-04-27in 245 d | A Study to Evaluate ALN-2232 in Participants With Obesity | ALNYAlnylam Pharmaceuticals | Phase 1/2 | Obesity | Recruiting |
| 2027-04-27in 245 d | A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China | AMGNAmgen | Phase 4 | Glucocorticoid-induced Osteoporosis | Active, not recruiting |
| 2027-04-27in 245 d | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | AMGNAmgen | Phase 3 | Obesity Disease | Active, not recruiting |
| 2027-04-27in 245 d | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | INCYIncyte Corporation | Phase 2 | Ovarian Cancer | Recruiting |
| 2027-04-27in 245 d | A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant | NVONovo Nordisk A/S | Phase 1 | Overweight | Not yet recruiting |
| 2027-04-27in 245 d | AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical Study | ZBHZimmer Biomet | Not applicable | Osteoarthritis | Active, not recruiting |
| 2027-04-28in 246 d | Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) | SNYSanofi | Phase 2 | Type 1 Diabetes | Active, not recruiting |
| 2027-04-29in 247 d | A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | SNYSanofi | Phase 4 | Atopic Dermatitis | Active, not recruiting |
| 2027-04-29in 247 d | Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | SNYSanofi | Phase 2 | Type 1 Diabetes | Active, not recruiting |
| Apr 2027≤ 248 d | A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms | 4151.TKyowa Kirin Co., Ltd. | Phase 1/2 | Hematologic Neoplasms | Recruiting |
| 2027-04-30in 248 d | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | 4568.TDaiichi Sankyo | Phase 1/2 | Solid Tumors | Recruiting |
| Apr 2027≤ 248 d | A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting | ABBVAbbVie | — | Axial Spondylarthritis (r-axSpA) | Active, not recruiting |
| Apr 2027≤ 248 d | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | ABBVAbbVie | Phase 3 | Ovarian Cancer | Active, not recruiting |
| Apr 2027≤ 248 d | A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China | ABBVAbbVie | — | Diabetic Macular Edema | Active, not recruiting |
| Apr 2027≤ 248 d | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | ABBVAbbVie | Phase 1 | Non-Hodgkin Lymphoma | Active, not recruiting |
| Apr 2027≤ 248 d | Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder | ABBVAbbVie | Phase 2 | Bipolar I or II Disorder | Recruiting |
| Apr 2027≤ 248 d | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Recruiting |
| Apr 2027≤ 248 d | A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants | ABCLAbCellera Biologics Inc. | Phase 1 | Healthy Volunteers | Active, not recruiting |
| Apr 2027≤ 248 d | A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) | ACOGAlpha Cognition, Inc | Phase 4 | Alzheimer's Disease | Recruiting |
| 2027-04-30in 248 d | Acalabrutinib Real World Italian obSErvational Study -ARISE | AZNAstraZeneca | — | Chronic Lymphocytic Leukemia | Active, not recruiting |
| 2027-04-30in 248 d | DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns | AZNAstraZeneca | — | Lung Cancer | Recruiting |
| 2027-04-30in 248 d | Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | AZNAstraZeneca | — | Asthma | Recruiting |
| 2027-04-30in 248 d | Mavacamten Pregnancy Surveillance Program | BMYBristol-Myers Squibb | — | Hypertrophic Cardiomyopathy | Recruiting |
| Apr 2027≤ 248 d | Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | BSXBoston Scientific Corporation | Not applicable | Atrial Fibrillation | Recruiting |
| Apr 2027≤ 248 d | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | CLYMClimb Bio, Inc. | Phase 1 | Systemic Lupus Erythematosus | Recruiting |
| Apr 2027≤ 248 d | Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant | COCHEnvoy Medical Corporation | Not applicable | Sensori-Neural Deafness, Sensorineural Hearing Loss, Sensorineural Hearing Loss (Disorder), Sensorineural Hearing Loss, Bilateral, Sensorineural Hearing Loss, Profound, Sensorineural Hearing Loss, Severe | Active, not recruiting |
| Apr 2027≤ 248 d | Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus | GKOSGlaukos Corporation | Phase 2 | Keratoconus | Recruiting |
| 2027-04-30in 248 d | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | IDYAIDEAYA Biosciences | Phase 2 | Uveal Melanoma | Active, not recruiting |
| 2027-04-30in 248 d | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | INCYIncyte Corporation | Phase 1 | Myelofibrosis | Active, not recruiting |
| 2027-04-30in 248 d | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | INCYIncyte Corporation | Phase 3 | NonSegmental Vitiligo | Recruiting |
| 2027-04-30in 248 d | Robotic-Assisted da Vinci System Prophylactic Nipple-Sparing Mastectomy | ISRGIntuitive Surgical | Not applicable | Nipple Sparing Mastectomy | Active, not recruiting |
| 2027-04-30in 248 d | IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery | ISRGIntuitive Surgical | Phase 3 | Ureter Injury | Recruiting |
| Apr 2027≤ 248 d | DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea. | IXHLIncannex Healthcare Ltd | Phase 2 | Obstructive Sleep Apnea | Recruiting |
| Apr 2027≤ 248 d | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | KODKodiak Sciences Inc | Phase 3 | Macular Edema Secondary to Inflammation | Recruiting |
| Apr 2027≤ 248 d | Selinexor and Backbone Treatments of Multiple Myeloma Patients | KPTIKaryopharm Therapeutics Inc | Phase 1/2 | Multiple Myeloma | Recruiting |
| Apr 2027≤ 248 d | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | KYTXKyverna Therapeutics | Phase 2 | Multiple Sclerosis | Active, not recruiting |
| Apr 2027≤ 248 d | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | LLYEli Lilly and Company | Phase 1/2 | Lung Cancer | Active, not recruiting |
| Apr 2027≤ 248 d | A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | LLYEli Lilly and Company | Phase 2 | Osteoarthritis | Recruiting |
| Apr 2027≤ 248 d | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | LLYEli Lilly and Company | Phase 1 | Non-Hodgkin Lymphoma | Recruiting |
| Apr 2027≤ 248 d | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | LLYEli Lilly and Company | Phase 1 | Non-Hodgkin Lymphoma | Recruiting |
| Apr 2027≤ 248 d | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain | LLYEli Lilly and Company | Phase 2 | Chronic Pain, Low Back Pain | Recruiting |
| Apr 2027≤ 248 d | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain | LLYEli Lilly and Company | Phase 2 | Osteoarthritis | Recruiting |
| Apr 2027≤ 248 d | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | LONALeonaBio | Phase 3 | Breast Cancer | Recruiting |
| Apr 2027≤ 248 d | Micra Transcatheter Pacing System Post-Approval Registry | MDTMedtronic | — | Bradycardia | Active, not recruiting |
| Apr 2027≤ 248 d | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | MIRMMirum Pharmaceuticals, Inc. | Phase 2 | Primary Biliary Cholangitis, PBC | Recruiting |
| Apr 2027≤ 248 d | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | MNOVMediciNova | Phase 2/3 | Amyotrophic Lateral Sclerosis | Active, not recruiting |
| 2027-04-30in 248 d | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | NANO.PANanobiotix | Phase 1 | Head and Neck Cancer | Active, not recruiting |
| Apr 2027≤ 248 d | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | NKTXNkarta, Inc. | Phase 1/2 | Lupus Nephritis | Recruiting |
| Apr 2027≤ 248 d | EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) | NTRANatera, Inc. | — | Single Gene NIPT | Recruiting |
| 2027-04-30in 248 d | STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON) | PFEPfizer | — | Respiratory Syncytial Virus | Active, not recruiting |
| Apr 2027≤ 248 d | CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation | PLSEPulse Biosciences, Inc. | Not applicable | Atrial Fibrillation | Recruiting |
| 2027-04-30in 248 d | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | RIGLRigel Pharmaceuticals | Phase 4 | Acute Myeloid Leukemia | Recruiting |
| 2027-04-30in 248 d | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | RLAYRelay Therapeutics, Inc. | Phase 1 | Solid Tumors | Recruiting |
| Apr 2027≤ 248 d | Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy | SPRYARS Pharmaceuticals, Inc. | Phase 4 | Allergic Reactions | Recruiting |
| Apr 2027≤ 248 d | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | VTVTvTv Therapeutics | Phase 3 | Type 1 Diabetes | Active, not recruiting |
| Apr 2027≤ 248 d | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems | VTVTvTv Therapeutics | Phase 2 | Type 1 Diabetes | Not yet recruiting |
| Apr 2027≤ 248 d | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | XENEXenon Pharmaceuticals Inc. | Phase 3 | Epilepsy and Seizure Disorders | Recruiting |
